Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
275 questions in 51 reviews · Stroke
current versionsNo studies 275 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Non‐pharmacological interventions vs placebo/usual care or different forms of intervention Satisfaction with intervention (secondary outcome) Not addressed · people within 3 months after stroke Interventions for sexual dysfunction following stroke (2020) · Cochrane | no estimate extracted | NR | No studies |
Non‐pharmacological interventions vs placebo/usual care or different forms of intervention Marital/relationship/partner satisfaction (secondary outcome) Not addressed · people within 3 months after stroke Interventions for sexual dysfunction following stroke (2020) · Cochrane | no estimate extracted | NR | No studies |
Non‐pharmacological interventions vs placebo/usual care or different forms of intervention Adverse effects (secondary outcome) Outcome measure: adverse effects · people within 3 months after stroke Interventions for sexual dysfunction following stroke (2020) · Cochrane | no estimate extracted | NR | No studies |
Non‐pharmacological interventions vs placebo/usual care or different forms of intervention Psychological well‐being (secondary outcome) Not addressed · people within 3 months after stroke Interventions for sexual dysfunction following stroke (2020) · Cochrane | no estimate extracted | NR | No studies |
Pharmacological interventions vs placebo/usual care or different forms of intervention Sexual satisfaction (primary outcome) Not addressed · men (aged between 23 and 45) with premature ejaculation within 3 months after stroke Interventions for sexual dysfunction following stroke (2020) · Cochrane | no estimate extracted | NR | No studies |
Pharmacological interventions vs placebo/usual care or different forms of intervention Quality of life (secondary outcome) Not addressed · men (aged between 23 and 45) with premature ejaculation within 3 months after stroke Interventions for sexual dysfunction following stroke (2020) · Cochrane | no estimate extracted | NR | No studies |
Pharmacological interventions vs placebo/usual care or different forms of intervention Psychological well‐being (secondary outcome) Not addressed · men (aged between 23 and 45) with premature ejaculation within 3 months after stroke Interventions for sexual dysfunction following stroke (2020) · Cochrane | no estimate extracted | NR | No studies |
Pharmacological interventions vs placebo/usual care or different forms of intervention Satisfaction with intervention (secondary outcome) Not addressed · men (aged between 23 and 45) with premature ejaculation within 3 months after stroke Interventions for sexual dysfunction following stroke (2020) · Cochrane | no estimate extracted | NR | No studies |
Non‐pharmacological interventions vs placebo/usual care or different forms of intervention Sexual satisfaction (primary outcome) Not addressed · people within 3 months after stroke Interventions for sexual dysfunction following stroke (2020) · Cochrane | no estimate extracted | NR | No studies |
High‐dose VKA vs standard‐dose VKA Adverse events · people with antiphospholipid syndrome and a history of stroke or thromboembolic events Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in… (2020) · Cochrane | no estimate extracted | NR | No studies |
Standard‐dose VKA plus single antiplatelet agent vs standard‐dose VKA Adverse events · people with antiphospholipid syndrome and a history of stroke or thromboembolic events Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in… (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Number of patients with all vascular events (stroke, MI, non‐fatal cardiac arrest, unstable angina requiring revascularisation, vascular death) at 90 days and at 1 year · patients with TIA or ischaemic stroke Anti‐inflammatory therapy for preventing stroke and other vascular events after ischaemic stroke or… (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Number of patients with safety events (total AEs, infections, SAEs) · patients with TIA or ischaemic stroke Anti‐inflammatory therapy for preventing stroke and other vascular events after ischaemic stroke or… (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Number of patients with recurrent stroke (fatal and non‐fatal) at 90 days and at 1 year · patients with TIA or ischaemic stroke Anti‐inflammatory therapy for preventing stroke and other vascular events after ischaemic stroke or… (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Number of patients with all‐cause death · patients with TIA or ischaemic stroke Anti‐inflammatory therapy for preventing stroke and other vascular events after ischaemic stroke or… (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Number of patients with cardiovascular death · patients with TIA or ischaemic stroke Anti‐inflammatory therapy for preventing stroke and other vascular events after ischaemic stroke or… (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Number of patients with infection · patients with TIA or ischaemic stroke Anti‐inflammatory therapy for preventing stroke and other vascular events after ischaemic stroke or… (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Number of patients with non‐scheduled hospitalisation · patients with TIA or ischaemic stroke Anti‐inflammatory therapy for preventing stroke and other vascular events after ischaemic stroke or… (2020) · Cochrane | no estimate extracted | NR | No studies |
Motor neuroprosthesis vs another assistive technology device Independence in activities of daily living · promoting recovery of function after stroke Motor neuroprosthesis for promoting recovery of function after stroke (2020) · Cochrane | no estimate extracted | NR | No studies |
Citicoline vs placebo or standard treatment Quality of life (at the time of · people with acute ischemic stroke Citicoline for treating people with acute ischemic stroke (2020) · Cochrane | no estimate extracted | NR | No studies |
Flunarizine vs placebo Hypotension during treatment period · people with acute ischemic stroke Calcium antagonists for acute ischemic stroke (2019) · Cochrane | no estimate extracted | NR | No studies |
Flunarizine vs placebo Mean systolic blood pressure during or at end of treatment · people with acute ischemic stroke Calcium antagonists for acute ischemic stroke (2019) · Cochrane | no estimate extracted | NR | No studies |
Isradipine vs placebo Death at the end of treatment · people with acute ischemic stroke Calcium antagonists for acute ischemic stroke (2019) · Cochrane | no estimate extracted | NR | No studies |
Isradipine vs placebo Recurrence of stroke at the end of · people with acute ischemic stroke Calcium antagonists for acute ischemic stroke (2019) · Cochrane | no estimate extracted | NR | No studies |
Isradipine vs placebo Adverse events during treatment period · people with acute ischemic stroke Calcium antagonists for acute ischemic stroke (2019) · Cochrane | no estimate extracted | NR | No studies |
Isradipine vs placebo Hypotension during treatment period · people with acute ischemic stroke Calcium antagonists for acute ischemic stroke (2019) · Cochrane | no estimate extracted | NR | No studies |
Isradipine vs placebo Mean systolic blood pressure during or at end of treatment · people with acute ischemic stroke Calcium antagonists for acute ischemic stroke (2019) · Cochrane | no estimate extracted | NR | No studies |
Other calcium antagonists vs placebo Death or dependency at end of · people with acute ischemic stroke Calcium antagonists for acute ischemic stroke (2019) · Cochrane | no estimate extracted | NR | No studies |
Other calcium antagonists vs placebo Mean systolic blood pressure during or at end of treatment · people with acute ischemic stroke Calcium antagonists for acute ischemic stroke (2019) · Cochrane | no estimate extracted | NR | No studies |
Attention training vs control Objective global measures · people with attention deficits following stroke Cognitive rehabilitation for attention deficits following stroke (2019) · Cochrane | no estimate extracted | NR | No studies |
Attention training vs control Objective global measures · people with attention deficits following stroke Cognitive rehabilitation for attention deficits following stroke (2019) · Cochrane | no estimate extracted | NR | No studies |
Interventions vs conservative management Symptomatic radiation necrosis ‒ not reported · adults with a brain arteriovenous malformation Interventions for treating brain arteriovenous malformations in adults (2019) · Cochrane | no estimate extracted | NR | No studies |
Interventions vs conservative management Quality of life ‒ not reported · adults with a brain arteriovenous malformation Interventions for treating brain arteriovenous malformations in adults (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Restitutive interventions vs control Functional ability in activities of daily living · stroke survivors with visual field defects Interventions for visual field defects in people with stroke (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Compensative interventions vs control Falls · stroke survivors with visual field defects Interventions for visual field defects in people with stroke (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Assessment/screening interventions vs control Visual field · stroke survivors with visual field defects Interventions for visual field defects in people with stroke (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Assessment/screening interventions vs control Extended activities of daily living · stroke survivors with visual field defects Interventions for visual field defects in people with stroke (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Assessment/screening interventions vs control Reading ability · stroke survivors with visual field defects Interventions for visual field defects in people with stroke (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Assessment/screening interventions vs control Falls · stroke survivors with visual field defects Interventions for visual field defects in people with stroke (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Assessment/screening interventions vs control Quality of life · stroke survivors with visual field defects Interventions for visual field defects in people with stroke (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Restitutive interventions vs control Extended activities of daily living · stroke survivors with visual field defects Interventions for visual field defects in people with stroke (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Assessment/screening interventions vs control Scanning ‐ cancellation · stroke survivors with visual field defects Interventions for visual field defects in people with stroke (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Restitutive interventions vs control Reading ability · stroke survivors with visual field defects Interventions for visual field defects in people with stroke (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Restitutive interventions vs control Falls · stroke survivors with visual field defects Interventions for visual field defects in people with stroke (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Restitutive interventions vs control Scanning ‐ cancellation · stroke survivors with visual field defects Interventions for visual field defects in people with stroke (2019) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Compensative interventions vs control Functional ability in activities of daily living · stroke survivors with visual field defects Interventions for visual field defects in people with stroke (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Rate of serious adverse events · patients with acute ischaemic or haemorrhagic stroke Antibiotic therapy for preventing infections in people with acute stroke (2018) · Cochrane | no estimate extracted | NR | No studies |
Percutaneous vascular interventions vs intravenous thrombolytic treatment Vascular status (recanalisation rate) Percutaneous vascular interventions versus intravenous thrombolytic treatment for acute ischaemic stroke (2018) · Cochrane | no estimate extracted | NR | No studies |
Diazepam vs placebo Other stroke scales · people with acute stroke Gamma aminobutyric acid (GABA) receptor agonists for acute stroke (2018) · Cochrane | no estimate extracted | NR | No studies |
RIC vs non‐RIC treating ischaemic stroke Improvement in neurological impairment ‐ not measured · people with ischaemic stroke Remote ischaemic conditioning for preventing and treating ischaemic stroke (2018) · Cochrane | no estimate extracted | NR | No studies |